Pfizer v CMA; Flynn Pharma v CMA (phenytoin sodium capsules) [Archived]
Published by a LexisNexis Competition expert
Practice notesPfizer v CMA; Flynn Pharma v CMA (phenytoin sodium capsules) [Archived]
Published by a LexisNexis Competition expert
Practice notes
CASE HUB
ARCHIVED–this archived case hub reflects the position at the date of the judgment of 7 June 2018; it is no longer maintained.
NOTE—on 20 December 2018, the Court of Appeal granted the CMA permission to appeal the CAT’s judgment of 7 June 2018
See further, timeline, commentary and related cases.
Case facts
| Outline | Flynn Pharma Limited and Flynn Pharma (Holdings) Limited v CMA (1275/1/12/17), Pfizer Inc. and Pfizer Limited (1276/1/12/17)–appeals to the CAT in relation to the CMA’s decision of 12 February 2016 in Case CE-9742–13 phenytoin sodium capsules. |
| Latest development | On 25 July 2018, the CAT issued a ruling in which it (i) refused both Flynn and Pfizer permission to appeal the CAT’s judgment of 7 June 2018 (ii) remitted the issue of abuse to the CMA for reconsideration in accordance with that judgment and (iii) confirmed that the timing of the remittal should be immediate (instead of staying the remittal until the final determination of any appeal). |
| Parties | Appellants: • Pfizer Inc. and Pfizer Limited (together Pfizer). |
Access this content for free with a 7 day trial of LexisNexis and benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 42 practice areas
Get your quote today and take step closer to being able to benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 36 practice areas
Get a LexisNexis quote
* denotes a required field
To view the latest version of this document and thousands of others like it,
sign-in with LexisNexis or register for a free trial.
Powered by Lexis+®
Jurisdiction(s):
United Kingdom
Key definition:
CMA definition
What does CMA mean?
means the competition and markets authority, the UK national competition authority
CONTACT US
